Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 3/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231784 | 0.85 | ALOX15 (0.38) | PTGS2PTGS1NQO2PARP1SLC6A2 | |
| SCHEMBL14077923 | 0.80 | PTGS2 (0.32) | PTGS2PTGS1NQO2SLC6A2SLC6A4 | |
| SCHEMBL3931101 | 0.80 | PTGS2 (0.39) | PTGS2PTGS1NQO2PARP1SLC6A2 | |
| SCHEMBL3929152 | 0.76 | PARP1 (0.35) | PARP1 | |
| SCHEMBL2287836 | 0.66 | ALOX15 (0.46) | PTGS2PTGS1NQO2ALOX15TUBB1 | |
| SCHEMBL13413339 | 0.65 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3ALOX15FFAR1 | |
| SCHEMBL5592068 | 0.65 | SLC6A2 (0.48) | NQO2SLC6A2SLC6A4SLC6A3ALOX15 | |
| SCHEMBL16231322 | 0.65 | SLC6A2 (0.44) | NQO2SLC6A2SLC6A4SLC6A3ALOX15 | |
| SCHEMBL2867341 | 0.64 | PARP1 (0.37) | PARP1 | |
| SCHEMBL4700596 | 0.64 | MIF (0.64) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044072-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | PTGS2 3233/4885PTGS1 2295/4885NQO2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.